このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

状態依存内受容、価値ベースの意思決定、内省

2026年10月1日 更新者:National Institute of Mental Health (NIMH)

Background:

Negative emotional states can affect a person s behavior as they make decisions. For example, hunger may make people more impatient; they may then make riskier choices. Other negative emotional states that can change behavior include stress, pain, and sadness. By learning more about how emotions affect thinking and behavior in healthy people, researchers hope to better understand how to identify and treat people with mental disorders.

Objective:

To learn how negative emotions affect the brain and decision-making behavior.

Eligibility:

Healthy people aged 18 to 55 years.

Design:

Participants will have 3 clinic visits in 3 weeks.

Participants will fill out questionnaires. They will be asked about their personal history, their personality, and state of mind.

For 2 visits, participants will be assigned to different groups. Each group will experience 1 type of emotional stressor:

Some participants will watch a video.

Some will have to do arithmetic problems.

Some will have heat applied to an arm or leg.

Some will experience cold by immersing their hand in ice water.

For a snack craving test, some will be tempted by food after a 4-hour fast.

During these tests, participants will have sensors attached to their bodies. They will be videotaped. Saliva samples will be collected.

After the stressors, participants will do tasks on a computer. They will need to make choices.

Some participants will perform these decision-making tasks while lying in a brain scanner for functional magnetic resonance imaging. The brain scan involves lying on a table that slides into a cylinder that takes images of the brain.

...

調査の概要

詳細な説明

Study Description:

This study involves a series of experiments consisting of within-subject experimental manipulations of state. In separate sub-studies, we will induce 5 types of negative valence states (negative emotion, loss, pain, stress, and craving) compared to a neutral state to test the hypothesis that negative valence states impact value-based decision-making and the neural mechanisms involved in decision-making.

Objectives:

Primary Objective: Determine the effect of induced negative valence states on value-based decision-making and examine how brain value representation during decision-making is affected by negative valence states.

Secondary Objectives: 1) Determine the role of interoception and metacognition as moderators of the effect of negative valence states on value-based decision-making. 2) Characterize state-specific effects on value-based decision-making. 3) Establish whether states can affect stable features of interoception and metacognition. 4) Build a classification model for state-specific detection using multimodal feature data. 5) Compare interoception across modalities (cardiac, respiratory, pain). 6) Characterize state-specific neuroendocrine profiles for gonadal, stress, and appetitive hormones. 7) Explore how psychological stress and negative affect alter self-reported enjoyment in value-based actions.

Endpoints:

Primary Endpoints: Choice behavior and brain activations in decision-making tasks: 1) willingness-to-pay, 2) risk aversion, 3) ambiguity

aversion, and 4) delay discounting. For MRI: 1) VMPFC BOLD, 2) VS BOLD, and 3) AI BOLD signal.

Secondary Endpoints: Behavior and neural activations in an interoceptive task and confidence reports: 1) interoceptive accuracy, 2) confidence bias, and 3) confidence sensitivity. Behavior and neural activations in an enjoyable goal-progress task and pleasure reports: 1) local goal progress, 2) pleasure experience. For MRI: 1) OFC BOLD, 2) vmPFC BOLD, 3) ACC BOLD, 4) VS BOLD, 5) network

connectivity.

研究の種類

介入

入学 (推定)

900

段階

  • 適用できない

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究連絡先

研究場所

    • Maryland
      • Bethesda、Maryland、アメリカ、20892
        • 募集
        • National Institutes of Health Clinical Center
        • コンタクト:
          • For more information at the NIH Clinical Center contact Office of Patient Recruitment (OPR)
          • 電話番号:TTY dial 711 800-411-1222
          • メール:ccopr@nih.gov

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

18年~55年 (大人)

健康ボランティアの受け入れ

はい

受講資格のある性別

全て

説明

  • INCLUSION CRITERIA:

Subject selections will be equitable among those individuals who meet the inclusion criteria. Every effort will be made to balance sex and race. In order to be eligible to participate in this study, an individual must meet all of the following criteria:

  • Ability of subject to understand and the willingness to sign a written informed consent document.
  • All sexes; Age 18 to 55.
  • Able to read and write in English to guarantee understanding of all written and spoken instructions, which are in English.

EXCLUSION CRITERIA:

An individual who meets any of the following criteria will be excluded from participation in this study:

For all experiments:

  • Unable to comply with study procedures or follow-up visits
  • Has any serious or unstable medical condition or history that in a clinician's assessment implies a cardiovascular, neurological, or physical risk from the study procedures performed to induce negative valence states. This may include chronic systemic disorders

that could worsen due to stress (e.g. uncontrolled hypertension, coronary artery disease for example a history of myocardial infarction or stable or unstable angina, or diabetes)

  • Has any self-reported current psychiatric diagnosis (based on self-reported medical history)
  • Scores >=29 on Beck Depression Inventory II or >=26 on Beck Anxiety Inventory
  • Endorses any kind of problematic substance-related, gambling, or other addictive behavior disorder (such as videogames, social-networking, online shopping, etc.) as indicated by scores >=6 on the Generalized Problematic Behavior Severity Index
  • Regular use of psychoactive medications or psychoactive substances
  • Regular use of corticosteroids
  • Is pregnant

For stress and pain induction:

  • Has a major medical condition or medical history that in a clinician s assessment could affect temperature sensitivity, pain thresholds, or ability to comply with study procedures. This may include cardiovascular, autonomic, neurological, psychiatric, or chronic systemic disorders (including but not limited to stroke, blindness, deafness, history of brain damage, neurodegenerative, neurotoxic or demyelinating disorder, or diabetes)
  • Has a medical condition that in a clinician s assessment might affect somatosensation (e.g., Raynaud s disease, peripheral neuropathy, or circulatory disorder)

For pain induction:

  • Has a current chronic pain condition or has had chronic pain in the past (painful condition lasting more than six months)
  • Has a dermatological condition such as scars or burns, or has had a tattoo in the testing region within the previous 4 weeks that might influence cutaneous sensibility
  • Regular and recent use of prescription or over-the-counter medication that has a significant effect on pain or heat perception. These include medications such as centralacting agents such as opiates (morphine, tramadol), antidepressants (amitriptyline, duloxetine, milnacipran), anticonvulsants (gabapentin, pregabalin), anxiolytics (barbiturates, benzodiazepines), hypnotics (zolpidem, sodium oxybate), antipsychotics (valproate, lithium, olanzapine), antimigraine agents (sumatriptan, ergotamine), and muscle relaxants (cyclobenzaprine, carisoprodol). Use of analgesic medications, such as non-steroidal anti-inflammatories, salicylates, and acetaminophen, taken on an as needed basis is acceptable as long as the last dose taken was within 5 half-lives of testing.

For craving induction:

  • Has a condition that in a clinician s assessment could preclude the ability to hold 4-6 hours of fasting or that is associated with a risk of hypoglycemia (such as diabetes, kidney disease, insulinoma, adrenal or pituitary tumors or disorders, or anorexia nervosa)
  • Is currently engaged in any kind of diet medically- or self-prescribed or endorses a very strong desire to start a diet that involves eliminating or decreasing carbohydrate consumption
  • Has a history of food allergies such as tree-nut or peanut allergy.

For MRI experiments:

  • Individuals with conditions that could pose a risk relating to the safety of the MRI procedure but do not meet specific exclusion criteria for all experiments or for specific inductions will be excluded from the MRI portion of the protocol but may participate in the Behavioral Sub-study. Such conditions include:
  • Those with ferromagnetic metal in the cranial cavity or eye (e.g. aneurysm clip, implanted neural stimulator, cochlear implant, ocular foreign body)
  • Those with an abnormality on a structural MRI
  • Those with an implanted cardiac pacemaker or auto-defibrillator
  • Those with an insulin pump
  • Those with an irremovable body piercing
  • Pregnancy (based on urine test completed within 24 hours prior to scan)
  • Left-handed (only for MRI sub-study and if thermal pain stimulation is involved)

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 主な目的:基礎科学
  • 割り当て:非ランダム化
  • 介入モデル:クロスオーバー割り当て
  • マスキング:なし(オープンラベル)

武器と介入

参加者グループ / アーム
介入・治療
実験的:1

within-subjects experimental study, where each subject will receive a neutral state and a negative state induction intervention in a cross-over design (counterbalanced order across participants).

Passive video watching with emotional valence

実験的:2

within-subjects experimental study, where each subject will receive a neutral state and a negative state induction intervention in a cross-over design (counterbalanced order across participants).

Real effort task

実験的:3

within-subjects experimental study, where each subject will receive a neutral state and a negative state induction intervention in a cross-over design (counterbalanced order across participants).

Thermal pain

実験的:4

within-subjects experimental study, where each subject will receive a neutral state and a negative state induction intervention in a cross-over design (counterbalanced order across participants).

Stress state induction

実験的:5

within-subjects experimental study, where each subject will receive a neutral state and a negative state induction intervention in a cross-over design (counterbalanced order across participants).

Snack craving induction

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
Value-based decision-making metrics
時間枠:Right after intervention

Value-based metrics such as delay discounting, which is a measure of an individual's preference for small immediate rewards over larger later rewards.

Right after intervention
BOLD signal in decision-making areas ROI
時間枠:Right after intervention

BOLD signal related to decision making tasks

Right after intervention

二次結果の測定

結果測定
メジャーの説明
時間枠
Confidence
時間枠:Right after intervention

Level of confidence on the accuracy or optimality of their behavior.

Right after intervention
Interoceptive accuracy
時間枠:Right after intervention

Interoceptive accuracy is a measure of an individual's ability to report on bodily sensations with precision.

Right after intervention

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

捜査官

  • 主任研究者:Silvia Lopez Guzman, M.D.、National Institute of Mental Health (NIMH)

出版物と役立つリンク

研究に関する情報を入力する責任者は、自発的にこれらの出版物を提供します。これらは、研究に関連するあらゆるものに関するものである可能性があります。

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (実際)

2023年7月25日

一次修了 (推定)

2029年12月31日

研究の完了 (推定)

2029年12月31日

試験登録日

最初に提出

2022年12月27日

QC基準を満たした最初の提出物

2022年12月27日

最初の投稿 (実際)

2022年12月28日

学習記録の更新

投稿された最後の更新 (実際)

2026年10月2日

QC基準を満たした最後の更新が送信されました

2026年10月1日

最終確認日

2026年9月25日

詳しくは

本研究に関する用語

個々の参加者データ (IPD) の計画

個々の参加者データ (IPD) を共有する予定はありますか?

はい

IPD プランの説明

This study will comply with the NIH Data Sharing Policy and Policy on the Dissemination of NIH-Funded Clinical Trial Information and the Clinical Trials Registration and Results Information Submission rule. As such, this trial will be registered at ClinicalTrials.gov, and results information from this trial will be submitted to ClinicalTrials.gov. In addition, every attempt will be made to publish results in peer-reviewed journals. @@@@@@@@@@@@All individual participant data that underlie results in a publication will be made publicly available. No Personal Identifiable Information will be shared, all data submitted to repositories will be deidentified.

IPD 共有時間枠

Data from this study may be requested from other researchers 1 year after the completion of the primary endpoint by contacting the NIMH Data Archive (NDA) for all behavioral data and OpenNeuro (www.openneuro.org) for all fMRI data. It will remain in said repositories indefinitely.

IPD 共有アクセス基準

All individual participant data that underlie results in a publication will be made public through the IMH Data Archive (NDA) and OpenNeuro (www.openneuro.org) repositories. Access criteria is defined by these repositories and will not be limited by analysis type.

IPD 共有サポート情報タイプ

  • SAP

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

いいえ

米国FDA規制機器製品の研究

いいえ

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。

購読する